Loading…
Employees: 55
Size Atea Pharmaceuticals (AVIR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $346M, the 2991st largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.31 on 6 Nov 2026.
Performance Over six months the shares fell 20.6%, against -22.1% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 20 in its peer set.
Short interest Short interest is 3.8% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$416,000 | -$416,000 | -$416,000 | -$416,000 | -$260,000 |
| EBITDA | -$183M | -$180M | -$193M | -$164M | -$130M |
| Net income | -$165M | -$158M | -$168M | -$136M | -$116M |
| Free cash flow | -$152M | -$132M | -$135M | -$85.4M | -$123M |
| Capital expenditure | $0 | $0 | $0 | $0 | $1.94M |
| Total debt | $424,000 | $843,000 | $1.64M | $2.40M | $3.12M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVIR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.4% | -8.4% | 7th lowest of 20 |
| 6-month return | -20.6% | -22.1% | 9th highest of 20 |
| Distance from 52-week high | -33.2% | -36.1% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | 29.9× | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | n/a | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | 4.3× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |